R L Dunbar
Affiliation: University of Pennsylvania
- Current Drug Options for Raising HDL CholesterolRichard L Dunbar
University of Pennsylvania School of Medicine and Children s Hospital of Philadelphia, PHI building, Suite 351, 39th and Market Streets, Philadelphia, PA 19104, USA
Curr Treat Options Cardiovasc Med 7:15-23. 2005..Targeting HDLC with pharmacologic therapy is a more difficult decision in moderate-risk patients, in whom therapy must be highly individualized...
- Measuring Physical Stigmata of Niacin-Associated Skin Toxicity by Colorimetry, White-Light Spectroscopy, Laser Doppler Flowmetry, and Thermometry in Combination with Symptom Perception Scoring: Methods to Aid Development of Niacin MimeticsRichard L Dunbar
University of Pennsylvania, United States
J Lipid Res . 2017..Surprisingly, each stigma's abruptness predicted symptom perception, whereas peak intensity did not. These methods are adaptable to study other rubefacient drugs, or dermatologic and vascular disorders...
- Niacin Alternatives for Dyslipidemia: Fool's Gold or Gold Mine? Part I: Alternative Niacin RegimensRichard L Dunbar
Department of Medicine, Division of Cardiovascular Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
Curr Atheroscler Rep 18:11. 2016..Given important gaps left by statin therapy, the established cardioprotective niacin regimen remains an important evidence-based therapy for the statin intolerant or statin averse. ..
- Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trialRichard L Dunbar
Division of Translational Medicine and Human Genetics, Perelman School of Medicine at the University of Pennsylvania, 3600 Spruce Street, 8046 Maloney Building, Philadelphia, PA, 19104 2699, USA
Lipids Health Dis 14:98. 2015..3 mmol/L (200 mg/dL) and <5.6 mmol/L (500 mg/dL) and at high cardiovascular risk...
- Slaying the metabolic syndrome. Are we battling the Hydra or the Chimera?R L Dunbar
University of Pennsylvania Medical School, Philadelphia, PA, USA
Minerva Endocrinol 29:89-111. 2004..We review the limited data available regarding metabolic syndrome, with a focus on expert opinion gleaned from clinical guidelines, and offer advice to the clinician from our own experience with this population...
- The unsung perils of peripheral arterial disease: a malady in search of a patientRichard L Dunbar
University of Pennsylvania Medical School, Philadelphia, PA 19104, USA
Prev Cardiol 8:108-13; quiz 114-5. 2005..This article will review the relationship between PAD and other vascular disease, emphasizing the role of PAD in prevention efforts...
- Demystifying triglycerides: a practical approach for the clinicianRichard L Dunbar
Cardiovascular Risk Intervention Program, University of Pennsylvania School of Medicine, Philadelphia, USA
Cleve Clin J Med 72:661-6, 670-2, 674-5 passim. 2005..The third report of the National Cholesterol Education Program's Adult Treatment Panel (ATP-III) provides a much-needed strategy for managing patients with high triglycerides, based on the best available evidence...
- Seeing red: flushing out instigators of niacin-associated skin toxicityRichard L Dunbar
Department of Medicine, Division of Experimental Therapeutics, Institute for Translational Medicine and Therapeutics, Pennsylvania 19104, USA
J Clin Invest 120:2651-5. 2010..These efforts bring us one step closer to solving a key limitation of an important cardioprotective drug and reveal that the skin response to niacin is much more complicated than previously thought...
- Potent and selective PPAR-alpha agonist LY518674 upregulates both ApoA-I production and catabolism in human subjects with the metabolic syndromeJohn S Millar
Departments of Pharmacology, University of Pennsylvania, 652 BRB II III, 421 Curie Blvd, Philadelphia, PA 19104, USA
Arterioscler Thromb Vasc Biol 29:140-6. 2009..We sought to determine the effect of a potent and highly specific PPAR-alpha agonist, LY518674, on apoA-I, apoA-II, and apoB-100 kinetics in humans with metabolic syndrome and low levels of HDL cholesterol (C)...